Try Alerts Free   |   Login
Health Care › Biological Products (No Diagnostic Substances)

ALEC Price Correlated With Financials For Alector

Free historical financial statements for Alector Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 14 quarters since 2019. Compare with ALEC stock chart to see long term trends.

ALEC Stock Compared to Quarterly

ALEC Income Statement

Revenue, Net:14852000
Revenue Per Share:0.1796
Selling, General & Admin Expense:14252000
Research & Development Expense:48348000
Total Operating Expenses:62600000
Operating Income:-47748000
Income Taxes:733000
Net Income:-46148000
Earnings Per Share, Basic:-0.56
Shares Outstanding, Basic Avg:82701539

ALEC Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:1347000
Net Cash from Operations:-49053000
Net Cash from Operations Per Share:-0.5931
Net Cash from Financing Activities:489000
Property, Plant & Equipment Purchases:1915000
Net Cash from Investing Activities:60530000
Net Change in Cash & Equivalents:11966000

ALEC Balance Sheet

Cash and Cash Equivalents:185703000
Short-Term Investments:574075000
Total Current Assets:774963000
Property, Plant & Equipment, Net:26289000
Total Assets:837038000
Accounts Payable:4546000
Total Short-Term Liabilities:160889000
Total Liabilities:583934000

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock Inc.
6,003,576 sh
178,917 sh
3%
$56,794
-$2,384
Vanguard Group Inc
5,753,194 sh
44,498 sh
1%
$54,426
-$3,574
Federated Hermes, Inc.
5,656,601 sh
-90,229 sh
-2%
$53,511
-$4,877
FMR LLC
4,724,184 sh
24,595 sh
1%
$44,691
-$3,057
Ecor1 Capital, LLC
4,056,548 sh
 
$38,375
State Street Corp
3,293,597 sh
-620,739 sh
-16%
$31,157
-$8,613
JPMorgan Chase & Co
2,384,091 sh
-90,798 sh
-4%
$22,553
-$2,591
Price T Rowe Associates Inc /Md/
1,743,391 sh
-104,734 sh
-6%
$16,493
-$2,284
Franklin Resources Inc
1,598,454 sh
-289,336 sh
-15%
$15,122
-$4,058
Geode Capital Management, LLC
1,118,528 sh
24,471 sh
2%
$10,581
-$534
Deerfield Management Company, L.P. (Series C)
1,055,192 sh
 
$9,982
Euclidean Capital LLC
980,894 sh
 
$9,279
Rubric Capital Management Lp
900,000 sh
 
$8,514
Renaissance Technologies LLC
720,583 sh
14,803 sh
2%
$6,817
-$3,240
Aqr Capital Management LLC
656,028 sh
303,497 sh
86%
$6,206
$2,624
Northern Trust Corp
593,807 sh
9,333 sh
2%
$5,618
-$2,710
Morgan Stanley
571,683 sh
-242,189 sh
-30%
$5,407
-$2,862
Goldman Sachs Group Inc
567,292 sh
147,775 sh
35%
$5,367
$1,105
Dafna Capital Management LLC
532,438 sh
-20,000 sh
-4%
$5,037
-$576
Charles Schwab Investment Management Inc
445,271 sh
17,263 sh
4%
$4,213
-$136
COMPANY PROFILE
1. The Company and Liquidity

Alector, Inc. (Alector or the Company) is a Delaware corporation headquartered in South San Francisco, California. Alector is a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Initial Public and Follow-on Offerings On February 7, 2019, the Company completed an initial public offering (IPO) through issuing and selling 9,739,541 shares of common stock at a public offering price of $ 19.00 per share, including 489,541 shares sold pursuant to the underwriters’ partial exercise of their option to purchase additional shares, resulting in aggregate net proceeds of $ 168.2 million, after deducting underwriting discounts and commissions and offering costs. Upon the closing of the IPO, all of the outstanding shares of convertible preferred stock automatically converted into 45,374,836 shares of common stock. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding. On January 30, 2020, the Company completed a follow-on offering through issuing and selling 9,602,500 shares of common stock at a public offering price of $ 25.00 per share, including 1,252,500 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, resulting in aggregate net proceeds of $ 224.5 million, after deducting underwriting discounts and commissions and estimated offering costs.

Data imported from Alector Inc SEC filings. Check original filings before making any investment decision.